You are here
Canagliflozin + metformin demonstrated superior reductions in body weight vs sitagliptin 100 mg + metformin at 52 weeks1
Secondary Endpoint: Adjusted Mean Change in Body Weight From Baseline at 52 Weeks (%)
- Canagliflozin 100 mg difference from sitagliptin: –2.4% (95% CI: –3.0, –1.8; P <0.001)
- Canagliflozin 300 mg difference from sitagliptin: –2.9% (95% CI: –3.4, –2.3; P <0.001)
Canagliflozin is not indicated for weight loss.
SELECT IMPORTANT SAFETY INFORMATION
- Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema and anaphylaxis, were reported with canagliflozin; these reactions generally occurred within hours to days after initiation. If reactions occur, discontinue canagliflozin, treat per standard of care, and monitor until signs and symptoms resolve.
A double-blind, placebo- and active-controlled study of 1284 patients who were inadequately controlled on metformin alone. Study consisted of a 2-week, single-blind, placebo run-in period, a 26-week, placebo- and active-controlled treatment period (period 1) followed by a 26-week, active-controlled treatment period (period 2). Patients were randomized to the addition of canagliflozin 100 mg, canagliflozin 300 mg, sitagliptin 100 mg, or placebo. The primary endpoint was the change in A1C from baseline through week 26; change in A1C from baseline through week 52 was a prespecified secondary endpoint.1
Learn about SYSTOLIC BLOOD PRESSURE CHANGE